Smbj Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 24-06-2024
- Paid Up Capital ₹ 5.00 M
as on 24-06-2024
- Company Age 7 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.40 Cr
as on 24-06-2024
- Revenue 56.75%
(FY 2023)
- Profit 594.52%
(FY 2023)
- Ebitda 21.80%
(FY 2023)
- Net Worth 11.45%
(FY 2023)
- Total Assets 46.40%
(FY 2023)
About Smbj Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹1.40 Cr.
Sunny Jain and Manish Kumar serve as directors at the Company.
- CIN/LLPIN
U74999HR2017PTC098839
- Company No.
320245
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jul 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Sonipat, Haryana, India
- Telephone
- Email Address
- Social Media-
What products or services does Smbj Pharmaceuticals Private Limited offer?
Smbj Pharmaceuticals Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Antacid Drugs, Cardiovascular Drugs & Medication, Kidney Drugs, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Common Disease Medicines, Pharmaceutical Syrup, Multivitamin Tablets & Capsules, Gastrointestinal Drugs.
Who are the key members and board of directors at Smbj Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manish Kumar  | Managing Director | 06-Aug-2022 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sunny Jain | Director | 06-Aug-2022 | Current |
Financial Performance of Smbj Pharmaceuticals.
Smbj Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 56.75% increase. The company also saw a substantial improvement in profitability, with a 594.52% increase in profit. The company's net worth Soared by an impressive increase of 11.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Smbj Pharmaceuticals?
In 2023, Smbj Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 04 Sep 2018 | ₹1.40 Cr | Open |
How Many Employees Work at Smbj Pharmaceuticals?
Smbj Pharmaceuticals has a workforce of 11 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Smbj Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Smbj Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
